EMA’s January 2026 PRAC statistics show 140 PSUR recommendations, along with reviews of risk management plans and study protocols and results. That is a useful snapshot of the scale of routine pharmacovigilance work happening in the background.
For readers new to the field, this is a valuable corrective. Drug safety is not only about crisis moments and major warnings. A large share of the real work is periodic, structured, and documentation-heavy.
That routine volume matters because it is part of how the system sustains oversight over time. In pharmacovigilance, quiet process often matters as much as visible action.
0 Comments